Friday, 13 November 2026European Markets

ACANTHE DEV. Stock Was Up By 17.38% On Monday

Loading stream...

(vianews) - the market ended the session with acanthe dev. (acan.pa) jumping 17.38% to €0.36 on monday, following the last session's downward trend. cac 40 fell 0.21% to €7,449.44, after two consecutive sessions in a row of gains, on what was a somewhat negative trend trading session today.

acanthe dev.'s last close was €0.31, 38.76% below its 52-week high of €0.50.

about acanthe dev.

as of december 31, 2022, acanthe développement's real estate portfolio represents an area of 9,374 m². during the year, the group sold, for €9.2 million, lots held in a building located on the left bank in paris. all of the group's buildings have been subject to appraisals, mainly carried out by the firm vif expertise on december 31, 2022. the overall appraised value of the property portfolio (investment properties and building occupied by the group) amounts to €117.1 million, an increase, at constant scope, of €1.6 million (+1.4%) compared to 2021. this increase in value confirms the relevant investment policy of the group in the central business district of paris. the appraised value of the assets stands at €117.1 million.

earnings per share

as for profitability, acanthe dev. has a trailing twelve months eps of €-0.08.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -8.6%.

revenue growth

year-on-year quarterly revenue growth grew by 7.7%, now sitting on 3.97m for the twelve trailing months.

more news about acanthe dev. (acan.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com